3 Japanese Dividend Stocks Paying Over 3% With Income That Can Keep Growing

Higher oil prices are feeding into inflation expectations and keeping government bond yields elevated. That mix often puts more focus on income that can grow faster than cash in the bank. Reliable dividend powerhouses with covered, growing payouts can offer a way to keep cash flow coming in when markets feel uncertain. This article highlights three stocks from the Dividend Powerhouses screen that fit that brief.

The three stocks covered below are just a starting sample, since the full Dividend Powerhouses screen surfaced 457 more companies with equally compelling income stories that are not included here. To see the wider opportunity set, head straight into the Dividend Powerhouses (3%+ Yield) screener to identify, compare, and analyze the highest conviction ideas for your watchlist.

Canon (TSE:7751)

Canon is a global hardware and imaging group that sits across office printers, cameras, medical systems, and industrial equipment, selling everything from multifunction printers and network cameras to CT scanners and semiconductor tools. Printing is the core engine at about ¥2,512.7b in revenue, with Imaging adding roughly ¥1,134.8b, Medical ¥578.8b, and Industrial ¥346.5b, while smaller lines and internal eliminations make up the rest. The company is a heavyweight in Japan and overseas, with a market value of about ¥3,930.7b.

Income focused investors may find Canon interesting because it combines a P/E near 11x and a discount to estimated cash flow value with signs of improving profitability, including net margins near 7.4% and rising earnings. At the same time, the dividend track record has been patchy and the balance sheet leans on higher risk external funding, so the payout and capital structure need watching. Recent share buybacks and award winning products in printing and imaging show management is still investing in the core franchises. However, the slower earnings growth outlook and governance concerns mean the full income story here is more nuanced than a simple high yield label suggests.

Canon’s low P/E, cash flow discount, and refreshed core products suggest that the market might be overlooking part of the income story. Get the full picture in the 4 key rewards and 1 important warning sign

Build your own dividend powerhouse shortlist

Canon and the two other stocks in this list all came out of the same screen, but the real opportunity is in setting filters that match your own income goals. Use our flexible Screener to mix valuation, dividends, and risk checks into a custom watchlist, or start with any of our curated Investing Ideas.

Tokio Marine Holdings (TSE:8766)

Tokio Marine Holdings is a global insurer offering a broad mix of non life and life insurance, reinsurance, and related financial services across Japan, the US, and other markets. Most revenue comes from overseas insurance at about ¥5,187.7b, with domestic property and casualty adding roughly ¥3,136.4b, domestic life about ¥354.1b, and solution and other business around ¥328.1b. The group is a heavyweight in the sector with a market value of roughly ¥14,353.3b.

Income investors may want Tokio Marine on their radar because it pairs a 3.16% dividend yield with active share buybacks and a plan to become a leaner, higher return insurer through its Re New initiative and equity divestments. At the same time, the stock carries a rich valuation versus peers and a recent drop in profit margins, while its push into areas such as carbon insurance and overseas credit means more exposure to complex risks. The interest here is whether that mix of disciplined capital returns, targeted growth in solution businesses, and higher forecast ROE can outweigh those pressures over time.

Tokio Marine’s rich valuation and capital return plans suggest that investors may be missing something in the story. See how its equity sales, buybacks, and overseas push fit together in the 3 key rewards and 1 important warning sign

Daiichi Sankyo Company (TSE:4568)

Daiichi Sankyo Company is a global pharmaceutical group focused on cancer, cardiovascular, metabolic, and neurological diseases, with a heavy tilt toward next generation oncology drugs such as Enhertu, Datroway, and Vanflyta. The business currently reports virtually all of its ¥2,223.2b in revenue from a single Pharmaceutical Operation segment, reflecting a focused portfolio, and it has a market value of about ¥5,106.2b. That scale and concentration give Daiichi Sankyo significant leverage to successful drug launches and pipeline outcomes.

Income investors may find Daiichi Sankyo Company interesting because it combines a 3.57% dividend yield with a growing portfolio of high value oncology drugs that are winning new approvals and reimbursement in major markets. Recent deals and approvals for Enhertu, Datroway, and Vanflyta point to a deeper pipeline and wider global reach. However, cash flow coverage of the dividend looks tight and profits lean heavily on a small group of blockbuster drugs, so any stumble in trials, pricing policy, or competition could affect both growth and income.

Daiichi Sankyo Company’s oncology engine looks powerful, yet the dividend still leans on a tight cash flow cushion. Get the full context in the analysis report for Daiichi Sankyo Company for the risks that might be hiding in plain sight.

Seeking Fresh Alternatives Before They Fly

Fresh ideas often move first, and slow research can get caught chasing momentum. Scan under the radar for now and look for quality opportunities before the broader market focuses on them. Consider acting promptly and thoughtfully.

• Identify potential turnarounds early and track 22 high quality undervalued stocks that currently remain outside the spotlight but show solid cash generation and balance sheet strength.
• Follow structural shifts in computing and monitor 26 quantum computing stocks positioned around next generation hardware, software, and enabling infrastructure before attention fully catches up.
• Keep your watchlist focused and rotate into 54 resilient stocks with low risk scores that combine resilient balance sheets with lower measured risk scores while prices still appear reasonable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com